LONDON (Alliance News) - Physiomics PLC Friday said it has signed a further extension to a virtual tumour project with a major global pharmaceutical company, which was first announced in March.
The systems biology company said the extension will cover predicting optimal regimens for a candidate compound and should be completed by the end of 2015.
The project will be performed on a fee-for-service basis.
"We are very pleased to have extended this collaboration once more, demonstrating the importance of Virtual Tumour to their drug discovery and development projects. This collaboration seems likely to continue well into the future," Chief Executive Mark Chadwick said in a statement.
Physiomics said it anticipates announcing an additional virtual tumour deal shortly.
Shares in Physiomics were trading down 2.9% at 0.0510 pence early Friday, having peaked at 0.064p immediately at the open.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)